CELG:NGS-Celgene Corporation

EQUITY | Drug Manufacturers | Nasdaq Global Select

Last Closing

USD 88.15

Change

0.00 (0.00)%

Market Cap

USD 93.78B

Volume

7.32M

Analyst Target

USD 97.66
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Celgene Corp is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-03-24 )

Largest Industry Peers for Drug Manufacturers

ETFs Containing CELG

MVUS:SW 3.57 % 0.00 %

N/A

N/A
SPMV:SW 3.57 % 0.00 %

N/A

N/A
LABS 0.00 % 0.45 %

N/A

N/A
SICK 0.00 % 0.95 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 37.54% 69% C- 85% B
Dividend Return N/A N/A N/A N/A F
Total Return 37.54% 69% C- 85% B
Trailing 12 Months  
Capital Gain 3.73% 63% D 68% D+
Dividend Return N/A N/A N/A N/A F
Total Return 3.73% 63% D 63% D
Trailing 5 Years  
Capital Gain 24.61% 73% C 58% F
Dividend Return N/A N/A N/A N/A F
Total Return 24.61% 73% C 51% F
Average Annual (5 Year Horizon)  
Capital Gain 0.40% 49% F 38% F
Dividend Return 0.40% 49% F 32% F
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 27.40% 76% C+ 49% F
Risk Adjusted Return 1.46% 49% F 31% F
Market Capitalization 93.78B 96% N/A 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 15.57 11% 30%
Price/Book Ratio 12.70 13% 7%
Price / Cash Flow Ratio 3.25 14% 29%
Price/Free Cash Flow Ratio 12.68 12% 32%
Management Effectiveness  
Return on Equity 82.47% 95% 96%
Return on Invested Capital 21.39% 97% 87%
Return on Assets 11.75% 92% 90%
Debt to Equity Ratio 439.50% 3% 4%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.